Science Explorer Back to mapMap
Discussion
Institution · Synta Pharmaceuticals (United States)

Most cited papers from Synta Pharmaceuticals (United States)

Synta Pharmaceuticals (United States)

What are the most cited papers from Synta Pharmaceuticals (United States)?

The most cited paper from Synta Pharmaceuticals (United States) is "A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium" (Zhenqiang Su et al., 2014), with 1,092 citations. Next come "The NLR Gene Family: A Standard Nomenclature" (984) and "Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region" (894).

Showing 50 of 60 papers. Every paper with more than 84 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium Zhenqiang Su et al. · Nature Biotechnology Open access161 authors 21 Aug 2014 1,092
2 The NLR Gene Family: A Standard Nomenclature Jenny P.‐Y. Ting et al. · Immunity Open access Mar 2008 984
3 Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region Hisham Mohamed Mehanna, T.J. Beech, Tom Nicholson et al. · Head & Neck Review 20 Jan 2012 894
4 Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors Vinit Kumar et al. · Cancer Cell Open access Nov 2017 670
5 The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia Ghayas C. Issa et al. · Nature Open access 15 Mar 2023 501
6 Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor Denise Aysel Yardley, Roohi R. Ismail-Khan, Bohuslav Melichar et al. · Journal of Clinical Oncology Open access 7 May 2013 420
7 Defective mast cell effector functions in mice lacking the CRACM1 pore subunit of store-operated calcium release–activated calcium channels Monika Vig, Wayne I. DeHaven, Gary St. J. Bird et al. · Nature Immunology Open access 2 Dec 2007 404
8 Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma Steven J O'Day, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni et al. · Journal of Clinical Oncology Open access 11 Feb 2013 403
9 Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment Evguenia M. Alexandrova, Alisha R. Yallowitz, Dun Li et al. · Nature Open access 22 May 2015 372
10 The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells Masazumi Nagai, Nha Huu Vo, Luisa Shin Ogawa et al. · Free Radical Biology and Medicine 17 Apr 2012 371
11 Elesclomol induces cancer cell apoptosis through oxidative stress Jessica R. Kirshner, Suqin He, Vishwasenani Balasubramanyam et al. · Molecular Cancer Therapeutics Open access Aug 2008 361
12 Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis Allan L. Klein, Massimo Imazio, Paul C Cremer et al. · New England Journal of Medicine Open access 16 Nov 2020 354
13 Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes Owen S. Fenton, Kevin J. Kauffman, James C. Kaczmarek et al. · Advanced Materials 6 Jul 2017 288
14 Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia Hannah J. Uckelmann, Stephanie M. Kim, Eric M. C. Wong et al. · Science Open access 30 Jan 2020 278
15 MEN1 mutations mediate clinical resistance to menin inhibition Florian Perner et al. · Nature Open access 15 Mar 2023 265
16 Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery Owen S. Fenton, Kevin J. Kauffman, Rebecca L. McClellan et al. · Advanced Materials Open access 18 Feb 2016 254
17 High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections Lixin Zhang et al. · Proceedings of the National Academy of Sciences Open access 5 Mar 2007 254
18 WTAP is a novel oncogenic protein in acute myeloid leukemia Hima Bansal, Q Yihua, Swaminathan P. Iyer et al. · Leukemia Open access 13 Jan 2014 249
19 Exploring novel bioactive compounds from marine microbes Lixin Zhang, Rong An, Jinping Wang et al. · Current Opinion in Microbiology Review 10 May 2005 246
20 Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report Muhammad M. Mohiuddin et al. · The Lancet Open access 29 Jun 2023 233
21 Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy Weiwen Ying, Zhenjian Du, Lijun Sun et al. · Molecular Cancer Therapeutics 6 Dec 2011 232
22 Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) Ghayas C. Issa et al. · Journal of Clinical Oncology Open access 9 Aug 2024 230
23 Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma Steven J O'Day, Rene C. Gonzalez, David H. Lawson et al. · Journal of Clinical Oncology Open access 14 Oct 2009 219
24 Inhibition of Vibrio biofilm formation by a marine actinomycete strain A66 Jianlan You, Xiaoli Xue, Lixiang Cao et al. · Applied Microbiology and Biotechnology 12 Jul 2007 214
25 Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer Jim Sang, Jaime Acquaviva, Julie C. Friedland et al. · Cancer Discovery Open access 26 Mar 2013 211
26 GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study Giacomo Davide De Luca et al. · The Lancet Rheumatology Open access 16 Jun 2020 208
27 Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin Joao Gamelas Magalhaes, Dana J. Philpott, Marie‐Anne Nahori et al. · EMBO Reports 7 Oct 2005 179
28 Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley et al. · Clinical Cancer Research Open access 18 Jul 2012 166
29 HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes Rina M. Mbofung et al. · Nature Communications Open access 31 Aug 2017 158
30 The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML Emily Heikamp, Jill A. Henrich, Florian Perner et al. · Blood Open access 28 Sep 2021 153
31 Natural Products and Drug Discovery Arnold L. Demain, Lixin Zhang · Humana Press eBooks Book chapter 16 Nov 2007 150
32 Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) Warren C. Fiskus, Steffen Boettcher, Naval Guastad Daver et al. · Blood Cancer Journal Open access 11 Jan 2022 142
33 Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol Ronald K. Blackman, Kahlin Cheung-Ong, Marinella Gebbia et al. · PLoS ONE Open access 11 Jan 2012 135
34 Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition Margarita M. Dzama, Marlene Steiner, Johanna Rausch et al. · Blood Open access 27 Jun 2020 131
35 Citicoline (CDP-Choline): Mechanisms of action and effects in ischemic brain injury Kay Jorgenson D'Orlando, Bobby W. Sandage · Neurological Research Aug 1995 129
36 HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models Luke J. Whitesell, Sandro Santagata, Marc L. Mendillo et al. · Proceedings of the National Academy of Sciences Open access 8 Dec 2014 128
37 Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial Maria Cinta Cid, Sebastian H. Unizony, Daniël Blockmans et al. · Annals of the Rheumatic Diseases Open access 9 Mar 2022 127
38 Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors Anna Berkenblit, Joseph P. Eder, David P. Ryan et al. · Clinical Cancer Research 15 Jan 2007 124
39 A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies Jonathan Wade Goldman, Robert N. Raju, Gregory A Gordon et al. · BMC Cancer Open access 25 Mar 2013 116
40 Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta Takashi Hashimoto, Leigh Ann Nattkemper, Hei Sung Kim et al. · Experimental Dermatology 15 Jan 2021 115
41 Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease Bruce E. Sands, Eric W. Jacobson, Thomas Sylwestrowicz et al. · Inflammatory Bowel Diseases 16 Nov 2009 115
42 Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise David A. Proia, Richard C. Bates · Cancer Research 21 Feb 2014 113
43 A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease Robert B. Burakoff, Charles F. Barish, Dennis Riff et al. · Inflammatory Bowel Diseases 27 Jun 2006 111
44 A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1) Suresh S. Ramalingam et al. · Annals of Oncology Open access 21 May 2015 110
45 The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors Tzu‐yin Lin, Misty D. Bear, Zhenjian Du et al. · Experimental Hematology Open access 27 Jul 2008 109
46 The Role of NLRP3 Inflammasome in Pericarditis Adolfo Gabriele Mauro, Aldo Bonaventura, Alessandra Vecchié et al. · JACC Basic to Translational Science Open access Feb 2021 106
47 Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines David A. James, Keizo Koya, Hao Li et al. · Bioorganic & Medicinal Chemistry Letters 20 Feb 2008 106
48 A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer Komal Jhaveri et al. · Clinical Breast Cancer 3 Jan 2014 104
49 Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study Carrie Lynn Kitko et al. · Journal of Clinical Oncology Open access 2 Dec 2022 103
50 Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib Jaime Acquaviva, Donald Lawrence Smith, John-Paul Jimenez et al. · Molecular Cancer Therapeutics 8 Jan 2014 103

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.